SCHEMBL4355529

SCHEMBL4355529

O=C1N=C(N2CCN(c3ncccc3Cl)CC2)SC1=CC=Cc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.67
NPC1 O15118 3/20 0.67
RAB9A P51151 3/20 0.67
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2C19 P33261 1/20 0.64
ALDH1A1 P00352 3/20 0.48
DCTPP1 Q9H773 1/20 0.43
ALOX5 P09917 1/20 0.43
ENPP2 Q13822 2/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2B Q13224 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HPGD P15428 1/20 0.41
HCRTR1 O43613 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SENP1 Q9P0U3 1/20 0.41
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347273 0.89 MAPT (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4364671 0.87 ALDH1A1 (0.65) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4364677 0.87 ALDH1A1 (0.65) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4360903 0.86 MAPT (0.74) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4348593 0.82 MAPT (0.69) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4353893 0.82 MAPT (0.51) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4356154 0.81 MAPT (0.81) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4348960 0.81 MAPT (0.52) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4348750 0.81 MAPT (0.66) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4351680 0.81 MAPT (1.00) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885NPC1 326/4885RAB9A 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.